Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Thiamazole
Dechra Regulatory B.V.
QH03BB02
Thiamazole
1.25 mg/tablet
Coated tablet
POM: Prescription Only Medicine as defined in relevant national legislation
thiamazole
Authorised
2013-09-13
Health Products Regulatory Authority 07 January 2019 CRN008S6T Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Felimazole 1.25 mg Coated tablets for cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains: ACTIVE SUBSTANCE Thiamazole 1.25 mg EXCIPIENTS Titanium Dioxide (E171) 0.51 mg Dispersed Ponceau 4R Lake (E124) 1.35 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Coated tablet. Red sugar-coated biconvex tablets 5.5 mm diameter. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the stabilisation of hyperthyroidism in cats prior to surgical thyroidectomy. For the long-term treatment of feline hyperthyroidism. 4.3 CONTRAINDICATIONS Do not use in cats suffering from systemic disease such as primary liver disease or diabetes mellitus. Do not use in cats showing signs of autoimmune disease. Do not use in animals with disorders of white blood cells, such as neutropenia and lymphopenia. Do not use in animals with platelet disorders and coagulopathies (particularly thrombocytopenia). Do not use in cases of hypersensitivity to thiamazole or the excipient, polyethylene glycol. Health Products Regulatory Authority 07 January 2019 CRN008S6T Page 2 of 7 Do not use in pregnant or lactating females. Please refer to section 4.7. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals If more than 10 mg per day is required animals should be monitored particularly carefully. Use of the product in cats with renal dysfunction should be subject to careful risk : benefit assessment by the clinician. Due to the effect thiamazole can have on reducing the glomerular filtration rate, the effect of therapy on renal function should be monitored closely as deterioration of an underlying condition may occur. Haematology must be monitored due to risk of leucopenia or haemolytic anaemia. Any animal that su Read the complete document